Blocking the calcium cascade in experimental acute renal failure.

Area of Science:

• Nephrology
• Cardiovascular Pharmacology
• Cellular Physiology

Background:

• Prolonged ischemia causes irreversible kidney cell injury, initiated by a calcium-dependent cascade.
• Intervention strategies target reducing cytosolic calcium, enhancing mitochondrial sequestration, or inhibiting calcium-calmodulin activation.

Purpose of the Study:

• To evaluate the protective effects of calcium channel blockers (verapamil), mitochondrial calcium sequestering agents (EHDP), and calcium-calmodulin inhibitors (TFP) against prolonged renal ischemia.
• To assess the impact of these agents on survival rates and renal function in a rat model.

Main Methods:

• 190 unilaterally nephrectomized rats underwent 90-minute renal artery occlusion.
• Rats received intraperitoneal injections of saline, verapamil, EHDP, or TFP one hour prior to surgery.
• Survival rates were determined at 10 days, and renal function (blood urea nitrogen, serum creatinine) was assessed post-surgery.

Main Results:

• Survival rates at 10 days were significantly higher in drug-treated groups: verapamil (87.5%), TFP (90%), and EHDP (60%) compared to controls (33%).
• No significant differences in renal function tests (blood urea nitrogen, serum creatinine) were observed among the control, TFP, and EHDP groups.
• Verapamil demonstrated a significant survival benefit (P < 0.005), as did TFP (P < 0.005) and EHDP (P < 0.01).

Conclusions:

• Calcium antagonists and related agents effectively protect kidneys from prolonged ischemic injury, increasing survival rates.
• Despite improved survival, these agents did not significantly improve renal function tests in the short term.
• The protective effect may involve delaying or preventing irreversible ischemic cell damage.